Pharmaceutical maker Merck & Co. reported higher sales and earnings for the fourth quarter, while Warner-Lambert Co. posted a loss that included a previously announced restructuring charge.
The results were within expectations, soothing investors who had feared worse.
Merck shares rose $1, to $35.75.
Warner-Lambert added 12.5 cents to end at $64.625, both in New York Stock Exchange composite trading.
Merck posted an 11% increase in net income to $674.2 million, or 56 cents a share, from $609.1 million, or 53 cents a share.
Sales rose 15% to $3 billion from $2.6 billion.
The quarterly results include the effect of the Medco Containment Services Inc. acquisition in November.
For the year, the Whitehouse Station, N.J., company's earnings rose 9.2% to $2.17 billion, or $1.87 a share, from $1.98 billion, or $1.72 a share.
Sales rose 8.6% to $10.5 billion from $9.66 billion.
The yearly results include Medco, the sale of Calgon Water Management Division, and a restructuring charge in 1993 and accounting changes in 1992.
Continuing operations are "doing well, and that's a good sign," said Jack Lamberton, an analyst at NatWest Securities Corp.
Sales, particularly in the U.S., were stronger than expected, he asserted.
Warner-Lambert reported a quarterly net loss of $196.9 million, or $1.46 a share, compared with net income of $137.6 million, or $1.02 a share, a year ago.
Sales rose 4% to $1.53 billion from $1.47 billion.
The Morris Plains, N.J., company's yearly profit declined 49% to $331 million, or $2.45 a share, from $643.7 million, or $4.78 a share.
Sales grew 3.5% to $5.79 billion from $5.6 billion.
The quarter included a $13.1 million gain on the sale of its chocolate/caramel business and a $468.3 million restructuring charge.
In addition, the year included a $70 million charge for the disposition of the Novon Products Group and accounting changes.
